Nxstage Medical, Inc. (NXTM) Tops Q3 EPS by 2c; Lowers FY12 Outlook

Nxstage Medical, Inc. (NASDAQ: NXTM) reported Q3 EPS of ($0.04), $0.02 better than the analyst estimate of ($0.06). Revenue for the quarter came in at $61.2 million versus the consensus estimate of $60.81 million.

Nxstage Medical, Inc. sees FY2012 EPS of $-0.28--0.26, versus prior guidance of $-0.32--0.25 and the consensus of $-0.29. Nxstage Medical, Inc. sees FY2012 revenue of $240-242 million, versus prior guidance of $240-245 million and the consensus of $241.40 million.

Nxstage Medical, Inc. sees FY2012 EPS of $-0.06--0.04, versus the consensus of $-0.05. Nxstage Medical, Inc. sees FY2012 revenue of $63-65 million, versus the consensus of $64.70 million.

For earnings history and earnings-related data on Nxstage Medical, Inc. (NXTM) click here.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Jefferies sees a buying opportunity in this S&P 500 sector
• Omega Flex (OFLX) Tops Q2 EPS by 27c
• Boxlight Corporation (BOXL) Tops Q2 EPS by 2050c